TY - STD TI - Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–88. ID - ref1 ER - TY - STD TI - Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003. ID - ref2 ER - TY - JOUR AU - McCormack, A. I. AU - Wass, J. A. AU - Grossman, A. B. PY - 2011 DA - 2011// TI - Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status JO - Eur. J. Clin. Invest. VL - 41 UR - https://doi.org/10.1111/j.1365-2362.2011.02520.x DO - 10.1111/j.1365-2362.2011.02520.x ID - McCormack2011 ER - TY - STD TI - Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. 2007;25(12):1470–5. ID - ref4 ER - TY - STD TI - Whitelaw BC, Dworakowska D, Thomas NW, Barazi S, Riordan-Eva P, King AP, et al. Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol. 2012;76(6):877–86. ID - ref5 ER - TY - STD TI - Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol. 2012;76(6):769–75. ID - ref6 ER - TY - STD TI - McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol. 2009;71(2):226–33. ID - ref7 ER - TY - JOUR AU - Lau, Q. AU - Scheithauer, B. AU - Kovacs, K. AU - Horvath, E. AU - Syro, L. V. AU - Lloyd, R. PY - 2010 DA - 2010// TI - MGMT immunoexpression in aggressive pituitary adenoma and carcinoma JO - Pituitary VL - 13 UR - https://doi.org/10.1007/s11102-010-0249-0 DO - 10.1007/s11102-010-0249-0 ID - Lau2010 ER - TY - JOUR AU - Bocangel, D. AU - Sengupta, S. AU - Mitra, S. AU - Bhakat, K. K. PY - 2009 DA - 2009// TI - p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor JO - Anticancer Res VL - 29 ID - Bocangel2009 ER - TY - JOUR AU - Blough, M. D. AU - Zlatescu, M. C. AU - Cairncross, J. G. PY - 2007 DA - 2007// TI - O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-2782 DO - 10.1158/0008-5472.CAN-06-2782 ID - Blough2007 ER - TY - STD TI - Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39–51. ID - ref11 ER - TY - STD TI - Salehi F, Scheithauer BW, Kros JM, Lau Q, Fealey M, Erickson D, et al. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas. J Neuro-Oncol. 2011;104(3):647–57. ID - ref12 ER - TY - JOUR AU - Alexander, J. M. AU - Biller, B. M. AU - Bikkal, H. AU - Zervas, N. T. AU - Arnold, A. AU - Klibanski, A. PY - 1990 DA - 1990// TI - Clinically nonfunctioning pituitary tumors are monoclonal in origin JO - J Clin Invest VL - 86 UR - https://doi.org/10.1172/JCI114705 DO - 10.1172/JCI114705 ID - Alexander1990 ER - TY - STD TI - Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JJ, Vance ML, et al. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab. 2010;95(11):E280–90. ID - ref14 ER - TY - JOUR AU - Myong, N. H. PY - 2010 DA - 2010// TI - Role of loss of o(6)-methylguanine dna methyltransferase (MGMT) expression in non-small cell lung carcinomas (NSCLCs): with reference to the relationship with p53 overexpression JO - Cancer Res Treat VL - 42 UR - https://doi.org/10.4143/crt.2010.42.2.95 DO - 10.4143/crt.2010.42.2.95 ID - Myong2010 ER - TY - STD TI - Konduri SD, Ticku J, Bobustuc GC, Sutphin RM, Colon J, Isley B, et al. Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis. Clin Cancer Res. 2009;15(19):6087–95. ID - ref16 ER - TY - STD TI - Bobustuc GC, Baker CH, Limaye A, Jenkins WD, Pearl G, Avgeropoulos NG, et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol. 2010;12(9):917–27. ID - ref17 ER - TY - JOUR AU - Grombacher, T. AU - Eichhorn, U. AU - Kaina, B. PY - 1998 DA - 1998// TI - p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents JO - Oncogene VL - 17 UR - https://doi.org/10.1038/sj.onc.1202000 DO - 10.1038/sj.onc.1202000 ID - Grombacher1998 ER - TY - JOUR AU - Harris, L. C. AU - Remack, J. S. AU - Houghton, P. J. AU - Brent, T. P. PY - 1996 DA - 1996// TI - Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene JO - Cancer Res VL - 56 ID - Harris1996 ER - TY - STD TI - Natsume A, Ishii D, Wakabayashi T, Tsuno T, Hatano H, Mizuno M, et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 2005;65(17):7573–9. ID - ref20 ER - TY - JOUR AU - Xu, G. W. AU - Mymryk, J. S. AU - Cairncross, J. G. PY - 2005 DA - 2005// TI - Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin JO - J. Neurooncol VL - 74 UR - https://doi.org/10.1007/s11060-004-6601-3 DO - 10.1007/s11060-004-6601-3 ID - Xu2005 ER - TY - STD TI - Lai JC, Cheng YW, Goan YG, Chang JT, Wu TC, Chen CY, et al. Promoter methylation of O(6)-methylguanine-DNA-methyltransferase in lung cancer is regulated by p53. DNA Repair (Amst). 2008;7(8):1352–63. ID - ref22 ER - TY - JOUR AU - Mete, O. AU - Ezzat, S. AU - Asa, S. L. PY - 2012 DA - 2012// TI - Biomarkers of aggressive pituitary adenomas JO - J Mol Endocrinol VL - 49 UR - https://doi.org/10.1530/JME-12-0113 DO - 10.1530/JME-12-0113 ID - Mete2012 ER - TY - STD TI - Salehi F, Scheithauer BW, Kovacs K, Horvath E, Syro LV, Sharma S, et al. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas. Neurosurgery. 2012;70(2):491–6. 496. ID - ref24 ER - TY - JOUR AU - Zhou, Y. AU - Zhang, X. AU - Klibanski, A. PY - 2014 DA - 2014// TI - Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma JO - Mol Cell Endocrinol VL - 386 UR - https://doi.org/10.1016/j.mce.2013.09.006 DO - 10.1016/j.mce.2013.09.006 ID - Zhou2014 ER - TY - STD TI - Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82(3):876–83. ID - ref26 ER - TY - JOUR AU - Knosp, E. AU - Steiner, E. AU - Kitz, K. AU - Matula, C. PY - 1993 DA - 1993// TI - Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings JO - Neurosurgery VL - 33 UR - https://doi.org/10.1227/00006123-199310000-00008 DO - 10.1227/00006123-199310000-00008 ID - Knosp1993 ER - TY - JOUR AU - Saeger, W. AU - Ludecke, D. K. AU - Buchfelder, M. AU - Fahlbusch, R. AU - Quabbe, H. J. AU - Petersenn, S. PY - 2007 DA - 2007// TI - Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry JO - Eur J Endocrinol VL - 156 UR - https://doi.org/10.1530/eje.1.02326 DO - 10.1530/eje.1.02326 ID - Saeger2007 ER - TY - JOUR AU - Lau, Q. AU - Scheithauer, B. AU - Kovacs, K. AU - Horvath, E. AU - Syro, L. V. AU - Lloyd, R. PY - 2010 DA - 2010// TI - MGMT immunoexpression in aggressive pituitary adenoma and carcinoma JO - Pituitary VL - 13 UR - https://doi.org/10.1007/s11102-010-0249-0 DO - 10.1007/s11102-010-0249-0 ID - Lau2010 ER - TY - STD TI - Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350–4. ID - ref30 ER - TY - STD TI - Widhalm G, Wolfsberger S, Preusser M, Woehrer A, Kotter MR, Czech T, et al. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? Cancer. 2009;115(5):1070–80. ID - ref31 ER - TY - STD TI - Zuhur SS, Tanik C, Karaman O, Velet S, Cil E, Ozturk FY, et al. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern. Endocrine. 2011;40(2):222–7. ID - ref32 ER - TY - STD TI - Wang Y, Li J, Tohti M, Hu Y, Wang S, Li W, et al. The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy. J Exp Clin Cancer Res. 2014;33:56. ID - ref33 ER - TY - STD TI - Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, et al. High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing’s disease. Eur J Endocrinol. 2009;161(4):553–9. ID - ref34 ER - TY - STD TI - Fealey ME, Scheithauer BW, Horvath E, Erickson D, Kovacs K, McLendon R, et al. MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications. Endocr Pathol. 2010;21(3):161–5. ID - ref35 ER - TY - JOUR AU - Silber, J. R. AU - Bobola, M. S. AU - Ghatan, S. AU - Blank, A. AU - Kolstoe, D. D. AU - Berger, M. S. PY - 1998 DA - 1998// TI - O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics JO - Cancer Res VL - 58 ID - Silber1998 ER - TY - JOUR AU - Esteller, M. AU - Hamilton, S. R. AU - Burger, P. C. AU - Baylin, S. B. AU - Herman, J. G. PY - 1999 DA - 1999// TI - Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia JO - Cancer Res VL - 59 ID - Esteller1999 ER - TY - STD TI - Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95(10):4592–9. ID - ref38 ER -